We are developing the first multivalent vaccine against the SARS coronavirus. Our vaccine is designed to protect not only against SARS-CoV-2 (COVID-19), the virus at the origin of the current pandemic, but also against the variants in circulation responsible for increased transmissibility or pathogenicity.
Phylex Biosciences
is a next-generation vaccine company uniquely located at
the crossroads of information technology and biotechnology.
the crossroads of information technology and biotechnology.